Pasithea Therapeutics (KTTAW) Stock Chart & Stock Price History $0.03 +0.01 (+71.79%) Closing price 08/1/2025 04:00 AM EasternExtended Trading$0.03 0.00 (0.00%) As of 08/1/2025 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock Pasithea Therapeutics Stock Price Performance The Pasithea Therapeutics (KTTAW) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has increased 49.72%, with a year-to-date return of -22.54%. In the past month, the stock has increased 69.62%, reflecting recent market activity. As of the latest close, Pasithea Therapeutics traded at $0.03 with a market cap of and volume of 100 shares. Receive KTTAW Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+71.79%1 Month Performance+69.62%3 Month Performance+19.11%Year-To-Date Performance-22.54%1 Year Performance+49.72% KTTAW Stock Chart for Saturday, August, 2, 2025 KTTAW Chart by TradingView Pasithea Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/01/2025$0.03$0.03$0.02$0.02100 shs$0.0007/31/2025$0.02$0.03+49.72%$0.02$0.02100 shs$0.0007/30/2025$0.02$0.02+5.29%$0.02$0.02145 shs$0.0007/29/2025$0.02$0.02+8.97%$0.02$0.023,756 shs$0.0007/28/2025$0.02$0.02-22.77%$0.02$0.023,756 shs$0.0007/25/2025$0.02$0.02$0.02$0.02100 shs$0.0007/24/2025$0.02$0.02$0.02$0.02100 shs$0.0007/23/2025$0.02$0.02-3.81%$0.02$0.02100 shs$0.0007/22/2025$0.02$0.02$0.02$0.0210,200 shs$0.0007/21/2025$0.02$0.02$0.02$0.0210,200 shs$0.00 Get the Latest News and Ratings for KTTAW and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 07/18/2025$0.02$0.02$0.02$0.0210,200 shs$0.0007/17/2025$0.02$0.02+2.94%$0.02$0.0210,200 shs$0.0007/16/2025$0.02$0.02$0.02$0.0210,200 shs$0.0007/15/2025$0.02$0.02+28.30%$0.02$0.0210,200 shs$0.0007/14/2025$0.02$0.02$0.02$0.022,000 shs$0.0007/11/2025$0.02$0.02$0.02$0.022,000 shs$0.0007/10/2025$0.02$0.02-12.86%$0.02$0.022,000 shs$0.0007/09/2025$0.02$0.02$0.02$0.021,000 shs$0.0007/08/2025$0.02$0.02+17.98%$0.02$0.021,000 shs$0.0007/07/2025$0.02$0.02+17.11%$0.02$0.02223 shs$0.0007/04/2025$0.02$0.02$0.03$0.027,200 shs$0.0007/03/2025$0.02$0.02-3.80%$0.03$0.027,200 shs$0.0007/02/2025$0.02$0.02+1.28%$0.03$0.027,200 shs$0.0007/01/2025$0.02$0.02-10.34%$0.02$0.021,600 shs$0.00 Related Companies 180 Life Sciences Stock Price Chart 4D pharma Stock Price Chart Aesther Healthcare Acquisition Stock Price Chart Ainos Stock Price Chart Alvotech Stock Price Chart Atlantic Coastal Acquisition Corp. II Stock Price Chart Biofrontera Stock Price Chart biote Stock Price Chart BriaCell Therapeutics Stock Price Chart Calithera Biosciences Stock Price Chart Receive KTTAW Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:KTTAW) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KTTAW Stock Alerts